OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders

Co-led by Longitude Capital and Enavate Sciences, with Significant Participation by Existing Investors Samsara BioCapital and NuevaBio MENLO PARK, Calif. – November 7, 2023 – OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced the successful completion of a $60 million Series A financing, bringing the […]

OrsoBio to Present Phase 1 Data for the Liver-Targeted LXR Inverse Agonist TLC-2716 in Development for Severe Hypertriglyceridemia and NASH at AHA’s Scientific Sessions 2023

Data confirm the safety, tolerability, and lipid lowering benefits  of TLC-2716 in healthy volunteers MENLO PARK, Calif.– November 6, 2023 (BUSINESS WIRE) – OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced initial safety, pharmacokinetic (PK), and pharmacodynamic data from its first-in-human, Phase 1 study of TLC-2716, a liver-targeted inverse […]

OrsoBio to Present Phase 1 Data for the Liver-Targeted Mitochondrial Protonophore TLC-6740 in Development for the Treatment of Obesity at ObesityWeek® 2023

Preliminary data from SAD cohorts confirm the safety of TLC-6740 and a PK profile consistent with once-daily, oral dosing Plasma exposures of TLC-6740 upon chronic dosing projected to provide large safety margins, while therapeutic efficacy expected at low doses   MENLO PARK, Calif. – October 16, 2023 (BUSINESS WIRE) – OrsoBio, Inc., a clinical-stage biopharmaceutical […]

Recent News

OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.